🇺🇸 PTGX — Protagonist Therapeutics, Inc.
Salud Compra fuertePrecio actual
135,26 USD
Máx. histórico
158,62
80 días
Caída desde máximo
-14,73%
Rango 52 semanas
76,70 – 160,81
Variación hoy
-5,66%
Cierre anterior
143,37
Rango de hoy
134,39 – 143,30
Volumen hoy
582.605
Peor caída histórica
-85,79%
01/09/2021 → 13/06/2022
Recuperado en 1001 días
Volatilidad anualizada ⓘ
89,33%
- Nombre completo
- Protagonist Therapeutics, Inc.
- Divisa
- USD
- Mercado
- NasdaqGM
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 141
- PER ⓘ
- 131,32 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 178,57 USD (puede no estar actualizado)
- Primera cotización
- 11/08/2016
- Precio actualizado
- hace 4 horas
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 12/10/2022 | 8,18 | 8,25 | 7,98 | 8,17 | +0,12% | 3,30% | 547.000 |
| 11/10/2022 | 8,06 | 8,35 | 7,87 | 8,16 | +0,99% | 5,96% | 631.800 |
| 10/10/2022 | 8,30 | 8,33 | 8,03 | 8,08 | -2,77% | 3,55% | 501.300 |
| 07/10/2022 | 8,51 | 8,56 | 8,22 | 8,31 | -3,93% | 4,05% | 889.700 |
| 06/10/2022 | 8,62 | 8,78 | 8,55 | 8,65 | +0,35% | 2,67% | 587.600 |
| 05/10/2022 | 8,70 | 8,80 | 8,33 | 8,62 | -2,38% | 5,32% | 610.800 |
| 04/10/2022 | 8,81 | 9,01 | 8,73 | 8,83 | +2,91% | 3,18% | 1.061.800 |
| 03/10/2022 | 9,06 | 9,08 | 8,36 | 8,58 | +1,78% | 7,95% | 891.300 |
| 30/09/2022 | 8,36 | 8,79 | 8,28 | 8,43 | +2,18% | 6,10% | 660.200 |
| 29/09/2022 | 8,70 | 8,79 | 8,07 | 8,25 | -6,36% | 8,28% | 939.400 |
| 28/09/2022 | 8,52 | 8,93 | 8,50 | 8,81 | +3,89% | 4,99% | 945.800 |
| 27/09/2022 | 8,42 | 8,60 | 8,24 | 8,48 | +3,41% | 4,30% | 828.400 |
| 26/09/2022 | 8,21 | 8,65 | 8,17 | 8,20 | -1,44% | 5,86% | 714.300 |
| 23/09/2022 | 8,27 | 8,43 | 8,06 | 8,32 | -0,48% | 4,47% | 908.000 |
| 22/09/2022 | 8,46 | 8,53 | 8,16 | 8,36 | -1,18% | 4,37% | 513.000 |
| 21/09/2022 | 8,53 | 8,67 | 8,08 | 8,46 | +0,95% | 6,92% | 1.150.400 |
| 20/09/2022 | 7,80 | 8,39 | 7,80 | 8,38 | +4,49% | 7,50% | 623.700 |
| 19/09/2022 | 8,16 | 8,34 | 7,83 | 8,02 | -4,07% | 6,31% | 700.200 |
| 16/09/2022 | 8,18 | 8,45 | 7,68 | 8,36 | +1,09% | 9,41% | 4.922.200 |
| 15/09/2022 | 8,18 | 8,37 | 8,14 | 8,27 | +0,49% | 2,75% | 831.300 |
| 14/09/2022 | 8,61 | 8,68 | 8,03 | 8,23 | -2,95% | 7,55% | 1.085.300 |
| 13/09/2022 | 8,67 | 8,79 | 8,45 | 8,48 | -5,78% | 3,92% | 1.271.200 |
| 12/09/2022 | 8,84 | 9,11 | 8,44 | 9,00 | +1,81% | 7,58% | 827.200 |
| 09/09/2022 | 9,16 | 9,20 | 8,78 | 8,84 | -3,07% | 4,59% | 568.000 |
| 08/09/2022 | 8,70 | 9,18 | 8,69 | 9,12 | +3,40% | 5,63% | 478.300 |
| 07/09/2022 | 8,36 | 8,84 | 8,36 | 8,82 | +5,13% | 5,74% | 775.300 |
| 06/09/2022 | 9,00 | 9,00 | 8,37 | 8,39 | -5,20% | 7,06% | 618.500 |
| 02/09/2022 | 9,35 | 9,35 | 8,77 | 8,85 | -3,59% | 6,20% | 720.200 |
| 01/09/2022 | 8,65 | 9,20 | 8,43 | 9,18 | +5,28% | 8,90% | 696.600 |
| 31/08/2022 | 8,85 | 9,04 | 8,64 | 8,72 | +0,11% | 4,52% | 718.900 |